SAN DIEGO — Dexcom announced that results from its CONNECT clinical trial, published in The New England Journal of Medicine, show that its G7 continuous glucose monitoring system significantly improves blood sugar control in adults with Type 2 diabetes who are not using insulin.
The randomized controlled trial found that participants using Dexcom G7 experienced an average 1.6 percentage-point reduction in A1C levels from a baseline of 8.8%, representing a 0.9 percentage-point greater reduction than those receiving routine care.
Participants using the device also spent approximately five additional hours per day within the recommended glucose range of 70 to 180 mg/dL compared with those receiving standard care.
“Publication of CONNECT in The New England Journal of Medicine represents a significant moment for the CGM category,” said Jake Leach, president and CEO of Dexcom.
“Nearly two decades after NEJM last published clinical data on real-time CGM, we now have compelling evidence demonstrating the impact this technology can have for the millions of people with Type 2 diabetes who are not using insulin,” Leach added.
The CONNECT study screened 440 participants across 22 primary care sites in the United States. Researchers evaluated whether continuous glucose monitoring could improve diabetes management among patients who had not yet progressed to insulin therapy.
At 26 weeks, 68% of participants using Dexcom G7 achieved an A1C below 7.5%, while 46% reached an A1C below 7.0%.
Improvements in glucose control were observed within the first week of device use and continued throughout the study.
The benefits were consistent across a broad range of patient characteristics, including age, sex, race, ethnicity, body mass index, duration of diabetes and medication use.
Among participants taking GLP-1 medications, continuous glucose monitoring produced an additional 0.9 percentage-point A1C reduction compared with routine care. Patients using only GLP-1 therapy at baseline showed the largest difference between treatment groups, at 1.3 percentage points.
Researchers also reported high device adherence, with 97% of participants continuing to use continuous glucose monitoring after 26 weeks, most on a daily basis.
“These results provide compelling evidence that CGM use can meaningfully improve glucose outcomes for people with Type 2 diabetes who are not using insulin,” said Dr. Roy W. Beck, medical director of the JAEB Center for Health Research and senior author of the study.
Beck said the findings support considering continuous glucose monitoring earlier in Type 2 diabetes treatment, before patients require insulin.
The study results were initially presented at the American Diabetes Association’s 2026 Scientific Sessions.
Dexcom said the findings strengthen the evidence supporting broader access to continuous glucose monitoring for people with Type 2 diabetes, including adults over age 65 and those managing their condition with non-insulin medications.
